Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPRISA 012A subcutaneous broadly neutralizing monoclonal antibody safety study
PACTR201808919297244Phase 1Completed
- Sponsor
- CAPRISA
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of VRC07-523LS and PGT121 in human immunodeficiency virus infection (HIV) (10 arms), sponsored by CAPRISA. Primary endpoints: Reactogenicity after subcutaneous administration and Adverse events. Started Oct 2018; status: completed.
02
Drugs
VRC07-523LSPGT121
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR201808919297244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201808919297244.